De novo design, combined with a high-throughput receptor-diversion microscopy-based screen, complementary display methods and functional assays, enabled the development of G-protein-coupled receptor-binding miniprotein agonists and antagonists targeting receptors implicated in itch, pain, cancer, metabolic disease and migraine.
- Edin Muratspahić
- David Feldman
- David Baker